Biogen

SPINRAZA

Manufacturer:

Biogen

Spinraza HCPCS:

J2326

HCPCS Code Descriptor:

Injection, nusinersen, 0.1 mg

Category:

J Code

Spinraza NDCs:

64406-0058-01

Primary Type:

Genetic Disorder

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intrathecal

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Spinraza:

SPINRAZA is a Genetic Disorder drug manufactured by Biogen and administered via the Intrathecal route of administration. The J Code: J2326 is aligned to the drug SPINRAZA.

SPINRAZA is an antisense oligonucleotide used for treatment of spinal muscular atrophy (SMA). SMA is caused by a mutation in chromosome 5q that leads to a deficiency in the SMN protein. SPINRAZA (J2326) may lead to inclusion of exon 7 and a full-length SMN protein. It is indicated for use in pediatric patients and adults.

ACCESS PRICING AND MORE BY REGISTERING

J2326 Added Date:

January 1, 2018

J2326 Effective Date:

January 1, 2018

J2326 Termination Date:

HCPCS Active

Spinraza billing and coding information can be found through Biogen at the link below:
Spinraza patient assistance information can be found through SMA360: Support Services from Biogen at the URL: https://www.spinraza.com/en_us/home/support-and-events
SPINRAZA prescribing information can be found at the link below:
Information regarding SPINRAZA’s side effects can be found at MedlinePlus